Diabetic Macular Edema - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Diabetic Macular Edema - Pipeline Review, H2 2016

Diabetic Macular Edema - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Diabetic Macular Edema - Pipeline Review, H2 2016
Published Jul 20, 2016
195 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Diabetic Macular Edema - Pipeline Review, H2 2016, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic

  
Source:
Document ID
GMDHC8286IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables92
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Diabetic Macular Edema Overview131
Therapeutics Development142
  Pipeline Products for Diabetic Macular Edema Overview141
  Pipeline Products for Diabetic Macular Edema Comparative Analysis151
Diabetic Macular Edema Therapeutics under Development by Companies164
Diabetic Macular Edema Therapeutics under Investigation by Universities/Institutes201
Diabetic Macular Edema Pipeline Products Glance214
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
  Unknown Stage Products241
Diabetic Macular Edema Products under Development by Companies253
Diabetic Macular Edema Products under Investigation by Universities/Institutes281
Diabetic Macular Edema Companies Involved in Therapeutics Development2937
  Aciont Inc.291
  ActiveSite Pharmaceuticals, Inc.301
  Adverum Biotechnologies, Inc.311
  Aerpio Therapeutics, Inc.321
  Allergan Plc331
  Ampio Pharmaceuticals, Inc.341
  Araim Pharmaceuticals, Inc.351
  Astellas Pharma Inc.361
  Boehringer Ingelheim GmbH371
  Chengdu Kanghong Pharmaceuticals Group Co., Ltd.381
  Clonz Biotech Private Limited391
  7 Coherus BioSciences, Inc.401
  EyeGate Pharmaceuticals, Inc.411
  EyeGene, Inc.421
  F. Hoffmann-La Roche Ltd.431
  Formycon AG441
  Genmab A/S451
  Icon Bioscience, Inc.461
  Kala Pharmaceuticals, Inc.471
  Kalvista Pharmaceuticals Ltd481
  Kowa Company, Ltd.491
  Mabion SA501
  NicOx S.A.511
  Oculis ehf521
  Ohr Pharmaceutical Inc.531
  Pfizer Inc.541
  Precision Ocular Ltd551
  pSivida Corp.561
  Regeneron Pharmaceuticals, Inc.571
  Santen Pharmaceutical Co., Ltd.581
  SciFluor Life Sciences, LLC591
  Senju Pharmaceutical Co., Ltd.601
  Stealth BioTherapeutics Inc.611
  Sucampo Pharmaceuticals, Inc.621
  ThromboGenics NV631
  Verseon Corporation641
  Xbrane Biopharma AB651
Diabetic Macular Edema Therapeutics Assessment6612
  Assessment by Monotherapy Products661
  Assessment by Combination Products671
  Assessment by Target683
  Assessment by Mechanism of Action713
  Assessment by Route of Administration742
  Assessment by Molecule Type762
Drug Profiles78102
  (aflibercept + nesvacumab) Drug Profile781
  abicipar pegol Drug Profile793
  ACX-107 Drug Profile821
  aflibercept biosimilar Drug Profile831
  AKB-9778 Drug Profile844
  ALG-1001 Drug Profile883
  Antibodies to Inhibit Hemopexin for Diabetic Macular Edema Drug Profile911
  ASP-440 Drug Profile921
  ASP-8232 Drug Profile931
  ASPPDC-010 Drug Profile941
  AVA-101 Drug Profile953
  BI-1026706 Drug Profile981
  Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications Drug Profile991
  cibinetide Drug Profile1003
  conbercept Drug Profile1032
  danazol Drug Profile1054
  dexamethasone acetate Drug Profile1094
  dexamethasone acetate Drug Profile1131
  dexamethasone dipropionate Drug Profile1141
  dexamethasone dipropionate XR Drug Profile1151
  difluprednate Drug Profile1161
  Drug for Diabetic Macular Edema Drug Profile1171
  Drugs for Retinal Diseases Drug Profile1181
  EBI-031 Drug Profile1191
  EG-Mirotin Drug Profile1201
  elamipretide Drug Profile1217
  fluocinolone acetonide SR Drug Profile1288
  JDE-006 Drug Profile1361
  KVD-001 Drug Profile1371
  loteprednol etabonate Drug Profile1383
  NCX-422 Drug Profile1411
  NCX-434 Drug Profile1422
  NM-108 Drug Profile1441
  OLX-303 Drug Profile1451
  PF-655 Drug Profile1463
  ranibizumab biosimilar Drug Profile1491
  ranibizumab biosimilar Drug Profile1502
  ranibizumab biosimilar Drug Profile1521
  ranibizumab biosimilar Drug Profile1531
  ranibizumab biosimilar Drug Profile1541
  RC-1 Alpha Drug Profile1551
  ripasudil Drug Profile1562
  RTU-1096 Drug Profile1582
  SF-0166 Drug Profile1601
  Small Molecule for Diabetic Macular Edema Drug Profile1611
  Small Molecule to Inhibit Kallikrein for Diabetic Macular Edema Drug Profile1621
  Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema Drug Profile1631
  Small Molecules to Inhibit Plasma Kallikrein for DME and HAE Drug Profile1642
  squalamine lactate Drug Profile1668
  teprotumumab Drug Profile1742
  TG-931 Drug Profile1761
  THR-149 Drug Profile1771
  triamcinolone acetonide Drug Profile1781
  VA-999272 Drug Profile1791
Diabetic Macular Edema Dormant Projects1803
Diabetic Macular Edema Discontinued Products1831
Diabetic Macular Edema Product Development Milestones18410
  Featured News &Press Releases1841
    Jul 07, 2016: Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-0311841
    Jun 13, 2016: Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial1841
    May 11, 2016: Alimera Sciences' ILUVIEN Data Presented at SFO 20161851
    May 10, 2016: Queens University Belfast to study the Innate Repair Activator ARA 290 in Diabetic Macular Edema1851
    May 06, 2016: Alimera Sciences ILUVIEN Data Presented At 2016 ARVO1861
    Apr 29, 2016: Eleven Biotherapeutics to Present Data on EBI-031 at the ARVO 2016 Annual Meeting1871
    Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease1881
    Jan 26, 2016: Ampio OptimEyes Study Results to be presented at The Association for Research in Vision and Ophthalmology (ARVO)1881
    Jan 15, 2016: Eleven Biotherapeutics provides an update for EBI-0311891
    Jan 05, 2016: Allegro Ophthalmics Announces Last Patient Enrolled in Del Mar Phase 2b Clinical Trial of Luminate for the Treatment of Diabetic Macular Edema1901
    Jan 04, 2016: Alimera Sciences Announces ILUVIEN J Code J7313 Is Now Active1901
    Nov 16, 2015: Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN Slows Diabetic Retinopathy Progression1911
    Nov 13, 2015: Allergan Presents EARLY Analysis Data at the American Academy of Ophthalmology Annual Meeting1911
    Oct 14, 2015: Ampio Pharmaceuticals Announces Updates On the Regulatory Path for FDA Approval of Optina, an Oral Treatment for Diabetic Macular Edema1921
    Oct 09, 2015: Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day1931
Appendix1942
  Methodology1941
  Coverage1941
  Secondary Research1941
  Primary Research1941
  Expert Panel Validation1941
  Contact Us1941
  Disclaimer1951

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Diabetic Macular Edema - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Macular-Edema-Pipeline-Review-H2-2016-2088-16249>
  
APA:
Global Markets Direct - Market Research. (2016). Diabetic Macular Edema - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Macular-Edema-Pipeline-Review-H2-2016-2088-16249>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.